Medifast (NYSE:MED) Updates FY 2026 Earnings Guidance

Medifast (NYSE:MED) updated its FY 2026 earnings guidance on Monday. The company provided earnings per share guidance of -1.750–0.250 for the period, compared to the consensus EPS estimate of -1.870. The company issued revenue guidance of $270.0 million-$300.0 million, compared to the consensus revenue estimate of $281.0 million. Medifast also updated its Q3 2026 guidance to -0.650–0.150 EPS.

Medifast Trading Down 1.1%

MED stock traded down $0.10 during midday trading on Monday, reaching $9.72. 230,646 shares of the company’s stock traded hands, compared to its average volume of 234,457. The stock’s 50-day moving average is $11.11 and its 200 day moving average is $11.05. The stock has a market cap of $108.14 million, a P/E ratio of -5.31 and a beta of 0.65. Medifast has a 52-week low of $9.22 and a 52-week high of $15.11.

Medifast (NYSE:MED) last released its quarterly earnings results on Monday, August 3rd. The specialty retailer reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.65) by $0.37. The business had revenue of $76.38 million during the quarter, compared to analyst estimates of $72.70 million. Medifast had a negative return on equity of 4.80% and a negative net margin of 5.78%.Medifast has set its FY 2026 guidance at -1.750–0.250 EPS and its Q3 2026 guidance at -0.650–0.150 EPS. As a group, research analysts expect that Medifast will post -1.97 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently issued reports on MED. Zacks Research raised shares of Medifast from a “hold” rating to a “strong-buy” rating in a report on Monday, July 13th. Weiss Ratings downgraded shares of Medifast from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, May 6th. One research analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $12.00.

Insider Buying and Selling

In related news, Director Scott Schlackman acquired 2,500 shares of the business’s stock in a transaction on Monday, May 11th. The stock was acquired at an average cost of $12.53 per share, with a total value of $31,325.00. Following the acquisition, the director directly owned 30,549 shares in the company, valued at $382,778.97. This represents a 8.91% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 3.70% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. BNP Paribas Financial Markets lifted its position in shares of Medifast by 103.1% in the third quarter. BNP Paribas Financial Markets now owns 2,338 shares of the specialty retailer’s stock worth $32,000 after buying an additional 1,187 shares in the last quarter. Quantbot Technologies LP bought a new stake in shares of Medifast in the 3rd quarter valued at approximately $37,000. Intesa Sanpaolo Wealth Management bought a new stake in Medifast in the fourth quarter worth $47,000. State of Wyoming bought a new stake in shares of Medifast in the 4th quarter worth about $59,000. Finally, Strs Ohio bought a new position in Medifast during the 1st quarter valued at about $78,000. Institutional investors own 95.51% of the company’s stock.

About Medifast

Medifast, Inc (NYSE: MED) is a health and wellness company specializing in clinically supported weight-loss, weight-management and healthy living products and services. Through its OPTAVIA brand, the company offers a range of meal replacement products, snacks, supplements and coaching programs designed to support metabolic health and sustainable lifestyle changes. Medifast markets its products directly to consumers via a network of independent distributors—known as OPTAVIA Coaches—who provide personalized guidance and support throughout the client’s weight‐loss journey.

Founded in 1980 by William Vitale and headquartered in Baltimore, Maryland, Medifast has grown into a nationally recognized provider of nutrition and weight‐management solutions.